How many drugs treat Asthma management?

Drug Landscape tracks 10 marketed treatments for Asthma management (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Asthma management?

Most recent: Bupivacaine Hydrochloride And Epinephrine — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/asthma-management.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Asthma management — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Asthma management (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Asthma management, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Omnaris	CICLESONIDE	Covis	ciclesonide	Glucocorticoid receptor	2006-01-01
Omnaris	Alvesco	Takeda Gmbh	ciclesonide	Glucocorticoid receptor	2006-01-01
Singulair	montelukast	Merck & Co.	Leukotriene receptor antagonist (LTRA)	Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2	1998-02-20
Accolate	ZAFIRLUKAST	Strides Pharma Intl	Leukotriene Receptor Antagonist [EPC]	Cysteinyl leukotriene receptor 1	1996-01-01
Flonase	fluticasone propionate	GSK (GlaxoSmithKline)	Inhaled/intranasal corticosteroid	Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor	1994-11-04
Pulmicort Respules	BUDESONIDE	AstraZeneca K.K.	Corticosteroid [EPC]	Glucocorticoid receptor	1994-01-01
Alocril	NEDOCROMIL	AbbVie	Mast Cell Stabilizer	G-protein coupled receptor 35	1992-01-01
Elocon	MOMETASONE FUROATE	Merck & Co.	Corticosteroid	Progesterone receptor	1987-01-01
Tornalate	BITOLTEROL	Sanofi	bitolterol	Beta-2 adrenergic receptor	1984-01-01
Intal	cromoglicic acid	Pfizer	Mast Cell Stabilizer	G-protein coupled receptor 35	1982-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-30 — Bupivacaine Hydrochloride And Epinephrine · FDA · approved · US
2026-03-26 — Norepinephrine Bitartrate In 5% Dextrose · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 8 drugs in Asthma management
Pfizer · 2 drugs in Asthma management
Pfizer Inc. · 2 drugs in Asthma management
Merck & Co. · 2 drugs in Asthma management
GSK (GlaxoSmithKline) · 1 drug in Asthma management
Genuine Research Center, Egypt · 1 drug in Asthma management
AstraZeneca K.K. · 1 drug in Asthma management
Marinomed Biotech AG · 1 drug in Asthma management
Creighton University · 1 drug in Asthma management
LEO Pharma · 1 drug in Asthma management
Mundipharma Research Limited · 1 drug in Asthma management
Imperial College London · 1 drug in Asthma management

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Asthma management:

Cite this brief

Drug Landscape (2026). Asthma management — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/asthma-management. Accessed 2026-06-10.

Asthma management full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing